Dr Adam M Hill, CEO of Oncimmune commented: “Today’s announcement further demonstrates the success of our partnership with Sabartech for the distribution of EarlyCDT Lung across the Iberian Peninsula. The news highlights the growing momentum behind our business and further validates our strategy of creating value through partnering to unlock the potential of the EarlyCDT portfolio.”
Oncimmune Holdings plc (LON:ONC), a leading global immunodiagnostics group, today announced Sabartech S.L., its existing distributor in Spain and Portugal, has today successfully signed an agreement with Vithas Group, the Spanish private healthcare group, to sell EarlyCDT® Lung as a screening test for early detection of lung cancer. In addition, Vithas Group’s laboratory is also promoting the test across Spain to further increase awareness of EarlyCDT Lung.
This is the latest in a series of commercial agreements to increase the reach of EarlyCDT Lung in large European and North American healthcare markets and validate the product’s increasing acceptance within major healthcare systems.
Vithas Group operates 48 hospitals and medical centres across Spain and has been growing strongly through the opening of new facilities, such as its Granada hospital in 2016, and strategic acquisitions such as Nisa Hospitals and Rincon Clinics in 2017. More than 5.2 million patients attend the Vithas Group medical centres, positioning the Vithas Group as the second-largest private medical group in Spain. In March 2019 we also announced a commercial agreement with Quirónsalud Group, Spain’s largest private hospital network with 46 hospitals, 56 outpatient centres and some 300 occupational risk centres.
Every year in Spain approximately 27,000 new cases of lung cancer are diagnosed and 23,000 deaths occur from the disease. Lung cancer is the largest cause of cancer-related deaths in Spain.[1]
